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Case report
UL54 foscarnet mutation in an hematopoietic stem
cell transplant recipient with cytomegalovirus
disease
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Abstract: We present a case of foscarnet (FOS) resistance arising
from a UL54 mutation after a short duration of FOS exposure, which
has not been previously described in a stem cell transplant recipient,
to our knowledge. We discuss the use of FOS to treat other viral
infections and the implications this may have for the development of
resistance mutations and treatment of cytomegalovirus disease.
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Cytomegalovirus (CMV) infection causes substantial
morbidity and mortality in hematopoietic stem cell
transplant (HSCT) recipients. In this patient population,
CMV disease may cause end-organ infection including
pneumonia, colitis or enteritis, hepatitis, or encephalitis
(1). Before the advent of effective antiviral therapy, 60–
70% of CMV-seropositive allogeneic HSCT recipients
developed CMV infection within 3 months after trans-
plantation (2). However, with the development of
antiviral therapy and preemptive and prophylactic
treatment strategies, the incidence of CMV disease
after stem cell transplantation has been markedly
reduced (3). Nevertheless, up to 20% of patients may
still develop CMV infection after HSCT, with 5%
developing infection within 3 months after transplanta-
tion (4).
Strategies designed to prevent CMV disease after
HSCT in at-risk patients include both prophylactic and
preemptive therapy. Preemptive therapy requires peri-
odic surveillance for viral reactivation with either pp65
antigen or CMV polymerase chain reaction (PCR)
assays for viral detection, with antiviral treatment
administered when virus is detected but before end-
organ disease occurs. Currently available antiviral
therapies for preemptive therapy include ganciclovir
(GCV) or valganciclovir (VGCV), foscarnet (FOS), and
cidofovir. GCV or VGCV is frequently used to treat
CMV infection in immunocompromised hosts. How-
ever, a primary toxicity of VGCV is myelosuppression.
In particular, VGCV may cause neutropenia (<500
neutrophils/lL) in >20% of HSCT patients in the peri-
transplant period, and is not recommended for admin-
istration if the absolute neutrophil count is <500 cells/
lL or if platelets are <25,000/lL (4, 5). Therefore, the
use of VGCV for CMV infection after HSCT may be
relatively contraindicated in those recipients in the
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pre-engraftment period or with delayed engraftment or
graft failure.
For patients intolerant of VGCV, FOS, a pyrophos-
phate analogue that directly inhibits the CMV viral
polymerase (6), is commonly used. In a randomized,
controlled study comparing preemptive therapy of
CMV infection in allogeneic HSCT recipients, FOS
was shown to be as effective as GCV, with a lower
incidence of neutropenia but a higher rate of nephro-
toxicity (7).
CMV therapy with either GCV or FOS may be
complicated by the emergence of antiviral resistance.
GCV resistance results primarily from mutations in the
UL97 gene, whose product phosphorylates GCV and is
required for GCV activation (8). FOS-resistant CMV
arises because of mutations in the UL54 gene, which
encodes the viral DNA polymerase (8). UL54 mutations
may also cause cross-resistance to both cidofovir and
GCV (9).
In this report, we present a case of CMV treatment
failure resulting from the emergence of FOS resistance
in an HSCT recipient previously treated with FOS for
human herpesvirus-6 (HHV-6) infection, and discuss
the possible implications for treating non-CMV viral
infections in similar patients.
Case report
The patient was a 46-year-old Caucasian man with acute
myelogenous leukemia, who underwent conditioning
chemotherapy with fludarabine and melphalan, fol-
lowed by a matched-unrelated donor allogeneic HSCT
in 2012. He was started on tacrolimus and received
methotrexate for graft-versus-host disease (GVHD)
prophylaxis on post-transplant days +1, +3, +6, and
+11. On day +11 he developed neutropenic fever, and
blood cultures grew Enterobacter species. Treatment
with piperacillin-tazobactam was initiated and he had
prompt resolution of his fever; subsequent blood
cultures were negative.
A bone marrow biopsy performed on day +21 was
acellular, suggesting primary graft failure. He then
received further conditioning chemotherapy with flu-
darabine and anti-thymocyte globulin, followed by a
second stem cell infusion on day +30, after which he
received GVHD prophylaxis with tacrolimus and
mycophenolate mofetil, and fungal prophylaxis with
voriconazole.
Despite continued broad-spectrum antimicrobial
therapy, the patient developed recurrent neutropenic
fevers. Clinical investigation revealed low-level HHV-6
viremia of 300 copies/mL on day +33 (Fig. 1). One
week later, HHV-6 viral load increased to 2200 copies/
mL. Because of concern that HHV-6 infection was
contributing to his fevers and poor stem cell engraft-
ment, antiviral therapy was initiated with FOS 90 mg/
kg/day, which he received from day +41 through day
+53. GCV was not used because of concerns regarding
myelosuppression. HHV-6 viremia had resolved when
assayed on day +43. Throughout the duration of HHV-6
viremia and treatment, weekly serum CMV PCR assays,
with a lower limit of detection of 300 copies/mL, were
negative.
During FOS treatment, the patient developed a
diffuse, maculopapular skin rash as well as gastroin-
testinal symptoms, including bloating, diarrhea, and
nausea. Mycophenolate mofetil was held, but his
symptoms persisted. Small bowel biopsy revealed
grade I GVHD, and methylprednisolone 2 mg/kg/day
and extracorporeal photopheresis were initiated. At
that time, he was found to have Epstein–Barr virus
(EBV) viremia of 3110 copies/mL and negative
serum CMV PCR (Fig. 1). Despite treatment for
acute GVHD, he continued to have diarrhea and
abdominal cramping, low-grade fevers, and pancyto-
penia. On day +61, serum EBV viral load was 7480
copies/mL. He received 1 dose of rituximab to
treat EBV reactivation with subsequent clearance of
viremia.
On day +61 (8 days after stopping FOS), he
developed CMV viremia of 1827 copies/mL. At the
time CMV reactivation was noted, his white blood
































Fig. 1. Temporal relationship of human herpesvirus-6 (HHV-6),
cytomegalovirus (CMV), and Epstein–Barr virus (EBV) viremia and
antiviral therapies to the first and second stem cell infusions. SCT,
stem cell transplant; ATG, anti-thymocyte globulin; MP, methylpred-
nisolone; FOS, foscarnet; GCV, ganciclovir.
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count was 1200 cells/lL. A colonoscopy was per-
formed to evaluate for CMV colitis and gut GVHD
and showed multiple shallow ulcerations in the
terminal ileum and descending colon. Colonic biop-
sies revealed grade I GVHD with histologic evidence
of CMV colitis. FOS was restarted at 90 mg/kg
intravenously every 12 h (IV q12h). After 14 days of
FOS treatment, serum CMV PCR increased to 11,705
copies/mL, a 0.5 log increase compared to the level
at initiation of therapy.
CMV resistance testing was performed and revealed
an E756K mutation in the UL54 gene, which had been
previously described as conferring FOS resistance and
reduced susceptibility to GCV and cidofovir (10). As
expected, no mutations were found in the UL97 gene.
FOS was stopped in favor of GCV 5 mg/kg IV q12h.
After 7 days of GCV therapy, repeat CMV PCR was 361
copies/mL. He developed significant neutropenia dur-
ing GCV treatment and required multiple doses of
granulocyte colony-stimulating factor to maintain a
neutrophil count >500 cells/lL, but he did have
resolution of his gastrointestinal symptoms. By day
+89, 2 weeks after starting GCV therapy, CMV PCR
was undetectable and therapy was stopped. In
6 months of follow-up thereafter, serum CMV PCR
remained undetectable.
Discussion
To our knowledge, this is only the second case in an
HSCT recipient identifying the development of FOS-
resistant CMV, without preceding UL97 mutations,
caused by prior GCV therapy. The rarity of isolated
FOS mutations is, in part, a result of the typical
practice of VGCV use preceding the use of FOS. In
HSCT recipients, however, the myelosuppressive tox-
icity of GCV leads to initial use of FOS more
commonly than in other populations (11, 12). Despite
this practice, the initial detection of UL54 FOS
resistance alone, without UL97 mutations, is rarely
reported. One report has been published of UL54
mutation L776M, after 23 days of GCV therapy and
116 days of FOS therapy, in an HSCT recipient (13).
This mutation conferred resistance to FOS and
borderline resistance to GCV, and the patient was
treated successfully with artesunate. A patient was
also reported who received prolonged FOS as salvage
therapy for human immunodeficiency virus and devel-
oped FOS resistance (14). In both of these cases, the
development of FOS resistance occurred after pro-
longed therapy, in stark contrast to only 28 days of
therapy in our patient.
Indeed, prolonged antiviral exposure, coupled with
ongoing viral replication because of host immune
suppression and/or inadequate antiviral dosing, are
the primary risk factors for the development of
resistance (8, 14–17). In 27 kidney transplant recipi-
ents, the mean duration of GCV therapy before
detection of resistance was 108 days (range 41–
205 days) (18). However, the initial exposure to FOS
for treatment of HHV-6 viremia in our patient was of
short duration, and, during this course of therapy,
weekly CMV serum PCR assays did not detect CMV,
while during the second 14-day course of FOS, only
low-level CMV viremia was measured. Therefore, the
emergence of antiviral resistance in this setting was
unexpected. It is possible that there was active CMV
replication in an end-organ tissue despite the absence
of detectable virus in the serum, as has been demon-
strated previously (19, 20).
In addition, the dose of FOS 90 mg/kg/day that he
received for treatment may have engendered FOS
resistance. No dosing recommendations have been
established for FOS therapy to treat HHV-6 infection.
One study of 6 SCT recipients reported variable
success of treatment for HHV-6 viremia with doses of
FOS ranging from 90 to 180 mg/kg/day (21). A second
study, by the same authors, assessing the safety of FOS
as prophylaxis for HHV-6 encephalitis in the early post-
SCT period, found that a dose of 90 mg/kg/day
prevented encephalitis in all 10 study patients, although
HHV-6 viremia did occur in 3 patients receiving
prophylaxis (11). Our patient received FOS 90 mg/
kg/day and had prompt resolution of HHV-6 viremia.
However, dosing recommendation for FOS treatment of
CMV infection is 90 mg/kg q12h, and for CMV
prophylaxis is 60 mg/kg every 8–12 h for 7 days,
followed by 90–120 mg/kg/day. As our patient
received a dose of FOS lower than that typically given
for CMV prophylaxis, and had no FOS exposure
previously, it is possible that this therapy led to the
emergence of the E756K mutation.
However, published studies of FOS therapy for CMV
indicate that resistance has not been described, even at
doses lower than the dose our patient received. In 313
HSCT recipients with CMV antigenemia or disease who
received FOS for therapy, the median initial FOS dose
was 88 mg/kg twice daily and no resistance was
reported (12). Also, no FOS resistance was noted in
110 HSCT recipients with CMV antigenemia treated
with FOS 60–90 mg/kg twice daily for 14–28 days (22),
making it unclear if profound immunosuppression or
the duration and intensity of FOS exposure played a
more significant role in the development of resistance
in our patient.
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Summary
This case demonstrates that isolated FOS-resistant CMV
may develop in HSCT recipients previously treated with
FOS. As CMV viremia had not previously been identified
in this patient, and theCMVviral load upon reinitiation of
FOS therapy was too low for accurate genotypic analysis,
we cannot be absolutely certain at what point in this
patient’s course the E756K mutation emerged. Fortu-
nately, the E756K mutation did not confer clinically
significant cross-resistance to GCV, but this case illus-
trates the danger of engendering resistance in CMV
through treatment of other viral infections with FOS,
even with short courses of treatment, in profoundly
immunosuppressed individuals.
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